ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
Rhea-AI Summary
ENvue Medical (NASDAQ: FEED) announced a three-year purchasing agreement renewal with a Group Purchasing Organization covering one of the largest U.S. non-profit health systems operating over 90 hospitals in 17 states. The contract secures contracted access through 2028, simplifying procurement and enabling faster adoption across the network.
The company said the renewal reduces facility-level procurement hurdles and creates a multi-year commercial foundation to drive broader utilization and expand its installed base.
Positive
- Contract covers >90 hospitals across 17 states through 2028
- Three-year term provides a durable contracting foundation
- Streamlines procurement by removing facility-level approvals
Negative
- No financial terms, volumes, or revenue impact disclosed
- Renewal duration limited to three years without longer-term commitment
News Market Reaction – FEED
In the May 7 session, FEED gained 5.60%, reflecting a notable positive market reaction. Argus tracked a peak move of +15.9% during that session. Argus tracked a trough of -12.1% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 9.4x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | New hospital customer | Positive | -4.4% | 40th U.S. hospital customer adopts ENvue platform, expanding installed base. |
| Apr 16 | Corporate update | Positive | -7.5% | Stockholder letter highlights 2025 progress, 39 hospitals, IP and reimbursement wins. |
| Mar 24 | Health system expansion | Positive | +58.0% | Purchase by major Michigan health system grows footprint to 39 hospitals. |
| Feb 24 | Patent allowance | Positive | +5.6% | USPTO Notice of Allowance for feeding tube with EM sensor and camera. |
| Jan 28 | Distribution partnership | Positive | +119.0% | Nationwide U-Deliver deal for reusable ENFit syringes via multiple channels. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operational and partnership news has sometimes produced large upside moves, but similar-quality updates have also seen negative or muted next-day reactions.
Over the past six months, ENvue Medical reported several commercial and strategic milestones. These included a nationwide ENFit syringe distribution partnership (Jan 28, 2026), patent portfolio expansion with an 18-claim USPTO Notice of Allowance (Feb 24, 2026), and steady growth of the ENvue Navigation Platform footprint to 39–40 U.S. hospitals by late March and April 2026. Some announcements led to sharp gains, others to pullbacks, underscoring inconsistent trading responses to otherwise constructive news like today’s GPO renewal.
Key Terms
group purchasing organization (gpo) financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Renewed agreement provides streamlined access to ENvue equipment and supplies across a network of more than 90 hospitals in 17 states
TYLER, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced a three-year purchasing agreement renewal with the Group Purchasing Organization (“GPO”) for one of the largest non-profit health systems in the United States, operating over 90 hospitals across 17 states.
The renewal ensures that hospitals and care sites within the network can access the ENvue™ Navigation Platform through established contracting pathways, without the need for individual procurement processes at the facility level.
Contracted access within a health system of this scale represents a significant commercial infrastructure advantage. Rather than navigating facility-by-facility value analysis committee approvals - a process that can take months - any participating hospital within the network can move directly to adoption. The three-year term locks that position through 2028, providing ENvue with a long-duration contracting foundation across a large and geographically distributed hospital network.
"This renewal is an important commercial milestone for ENvue. We believe that having established access within a network of more than 90 hospitals in the U.S. means our technology is one clinical decision away from adoption at any participating facility. It reflects confidence in our platform, removes a critical friction point for customers, and gives us a durable foundation from which to drive broader utilization across the network," stated Doron Besser, MD, Chief Executive Officer of ENvue Medical.
ENvue Medical remains focused on converting contracted access into active adoption, expanding its installed base within large health system networks, and building long-term recurring commercial relationships with leading healthcare institutions across the United States.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com
